Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity

Vaccine

Volumn 29, Issue 4, 2011, Pages 839-848

  Hallengärd, David ^a   Haller, B Kristian ^b   Petersson, Sarah ^a   Boberg, Andreas ^a   Maltais, Anna Karin ^c   Isaguliants, Maria ^a   Wahren, Britta ^a   Bråve, Andreas ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA vaccine; HIV; Protease

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS MUTATION;

AIDS VACCINES; ANIMALS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV PROTEASE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTANT PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 78650571310     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.083     Document Type: Article

References (36)

1. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(March (5102)):1745-1749.
2. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11(9):957-960.
3. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(January (1)):46-53.
4. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68(July (7)):4650-4655.
5. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3(February (2)):205-211.
6. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189(March (6)):991-998.
7. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001, 75(May (9)):4040-4047.
8. Lorenzen N., LaPatra S.E. DNA vaccines for aquacultured fish. Rev Sci Tech 2005, 24(April (1)):201-213.
9. Wahren B., Ljungberg K., Rollman E., Levi M., Zuber B., Kjerrstrom Zuber A., et al. HIV subtypes and recombination strains-strategies for induction of immune responses in man. Vaccine 2002, 20(May (15)):1988-1993.
10. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(November (10)):1482-1490.
11. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, (November).
12. Blanco R., Carrasco L., Ventoso I. Cell killing by HIV-1 protease. J Biol Chem 2003, 278(January (2)):1086-1093.
13. zur Megede J., Otten G.R., Doe B., Liu H., Leung L., Ulmer J.B., et al. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines. J Virol 2003, 77(June (11)):6197-6207.
14. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998, 72(February (2)):1497-1503.
15. Ko H.J., Ko S.Y., Kim Y.J., Lee E.G., Cho S.N., Kang C.Y. Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun 2005, 73(September (9)):5666-5674.
16. Uchijima M., Yoshida A., Nagata T., Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998, 161(November (10)):5594-5599.
17. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85(July (13)):4686-4690.
18. Sayer J.M., Liu F., Ishima R., Weber I.T., Louis J.M. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem 2008, 283(May (19)):13459-13470.
19. Boberg A., Sjostrand D., Rollman E., Hinkula J., Zuber B., Wahren B. Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization. Vaccine 2006, 24(May (21)):4527-4530.
20. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002, 302(October (1)):44-57.
21. Rydzanicz R.Z.X.S., Johnson P.H. Assembly PCR oligo marker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production. Nucleic Acids Res 2005, (33):521-525.
22. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008, 16(March-April (1)):62-68.
23. Simon M., Falk K.I., Lundkvist A., Mirazimi A. Exogenous nitric oxide inhibits Crimean Congo hemorrhagic fever virus. Virus Res 2006, 120(September (1-2)):184-190.
24. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997, 185(June (12)):2043-2051.
25. Roos A.K., Eriksson F., Timmons J.A., Gerhardt J., Nyman U., Gudmundsdotter L., et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009, 4(9):e7226.
26. Brave A., Ljungberg K., Boberg A., Rollman E., Engstrom G., Hinkula J., et al. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 2006, 24(May (21)):4524-4526.
27. Larke N., Im E.J., Wagner R., Williamson C., Williamson A.L., McMichael A.J., et al. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol 2007, 37(February (2)):566-577.
28. Ahlen G., Derk E., Weiland M., Jiao J., Rahbin N., Aleman S., et al. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 2009, 58(April (4)):560-569.
29. Ahlen G., Nystrom J., Pult I., Frelin L., Hultgren C., Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005, 192(December (12)):2112-2116.
30. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50(November (3-4)):201-212.
31. Karlsson A.C., Iversen A.K., Chapman J.M., de Oliviera T., Spotts G., McMichael A.J., et al. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One 2007, 2(2):e225.
32. Konya J., Stuber G., Bjorndal A., Fenyo E.M., Dillner J. Primary induction of human cytotoxic lymphocytes against a synthetic peptide of the human immunodeficiency virus type 1 protease. J Gen Virol 1997, 78(September (Pt 9)):2217-2224.
33. Shoeman R.L., Honer B., Stoller T.J., Kesselmeier C., Miedel M.C., Traub P., et al. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc Natl Acad Sci USA 1990, 87(August (16)):6336-6340.
34. Kearney M., Maldarelli F., Shao W., Margolick J.B., Daar E.S., Mellors J.W., et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 2009, 83(March (6)):2715-2727.
35. Todd M.J., Luque I., Velazquez-Campoy A., Freire E. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 2000, 39(October (39)):11876-11883.
36. Kim K.S., Jin D.B., Ahn S.S., Park K.S., Seo S.H., Suh Y.S., et al. HIV-1 protease has a genetic T cell adjuvant effect which is negatively regulated by proteolytic activity. J Virol 2010, (May 19).